AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Oxervate	Page:	1 of 2
Effective Date:	3/14/2025	Last Review Date:	2/19/2025
Applies to:	☒Illinois ☒New Jersey ☒Maryland ☒Florida Kids ☒Pennsylvania Kids ☒Virginia		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Oxervate under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication
Oxervate is indicated for the treatment of neurotrophic keratitis.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Oxervate

Policy/Guideline:

Prescriber Specialties
This medication must be prescribed by or in consultation with an ophthalmologist or optometrist.

Criteria for Initial Approval:

Neurotrophic keratitis
Authorization of 16 weeks (8 weeks total therapy per eye) may be granted for treatment of Stage 2 and Stage 3 neurotrophic keratitis when ALL the following criteria are met:

A. The member must experience persistent epithelial defects (PED) or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments (e.g., preservative free artificial tears).
B. There is evidence of decreased corneal sensitivity (e.g., cotton swab method, Cochet-Bonnet contact aesthesiometer, CRCERT-Belmonte non-contact aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
C. The member has not received a previous 8-week course of Oxervate in the affected eye.

Approval Duration and Quantity Restrictions:

Approval: 16 weeks (8 weeks total therapy per eye)

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Oxervate [package insert]. San Mateo, CA: Dompe U.S. Inc.; December 2024.
2. Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Opthalmol. 2018;125(9):1332-1343. doi: 10.1016/j.ophtha.2018.02.022
3. Cunha AN, Bunya VY, Woodward MA, et al. Neurotrophic keratitis. American Academy of Ophthalmology EyeWiki. Updated June 18, 2024. Accessed October 9, 2024. https://eyewiki.aao.org/Neurotrophic_Keratitis.